Literature DB >> 32381852

[Cutting Edge of Hepatic Artery Infusion Chemotherapy for Hepatocellular Carcinoma].

Yasuteru Kondo1, Ryo Fukuda.   

Abstract

Recently, the choices of treatments for hepatocellular carcinoma(HCC)were increasing since the several molecular targeting agents(MTA)were approved for treatment of advanced HCC patients. On the other hand, the transarterial chemoembolization( TACE)and hepatic artery infusion chemotherapy(HAIC)have been improved by various kinds of methods. The liver resection, radiofrequency ablation(RFA)and microwave coagulation(MWA)might achieve complete cure. However, the treatment indication of liver resection, RFA and MWA should be limited. Therefore, multidisciplinary treatment including HAIC, TACE, MTA, RFA, MWA, and liver resection should be considered to control HCC.

Entities:  

Year:  2020        PMID: 32381852

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  Tumor-feeding artery diameter reduction is associated with improved short-term effect of hepatic arterial infusion chemotherapy plus lenvatinib treatment.

Authors:  De-Di Wu; Xiao-Feng He; Chen Tian; Peng Peng; Chuan-Li Chen; Xue-Han Liu; Hua-Jin Pang
Journal:  World J Gastroenterol       Date:  2022-07-14       Impact factor: 5.374

2.  DEB-TACE combined with hepatic artery infusion chemotherapy might be an affordable treatment option for advanced stage of HCC.

Authors:  Yasuteru Kondo; Tatsuki Morosawa; Soichiro Minami; Yasuhito Tanaka
Journal:  Sci Rep       Date:  2022-10-07       Impact factor: 4.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.